Table 1.

Carbapenem-resistant Enterobacterales (CRE) crude incidence, by Emerging Infections Program site and epidemiological classification, 2012-2015, n = 1499

EIP Site	Crude incidence rates per 100,000 population (95% confidence cnterval)
	2012		2013		2014		2015		Overall
	CA	HCA	CA	HCA	CA	HCA	CA	HCA	CA	HCA
CO			0.12 (0.02, 0.34)	0.93 (0.60, 1.38)	0.04 (0.00, 0.21)	0.61 (0.35, 0.99)	0.33 (0.15, 0.63)	0.93 (0.60, 1.37)	0.16 (0.09, 0.28)	0.82 (0.63, 1.05)
GA	0.21 (0.09, 0.41)	4.16 (3.54, 4.86)	0.13 (0.04, 0.30)	4.11 (3.50, 4.81)	0.20 (0.09, 0.40)	3.90 (3.30, 4.57)	0.13 (0.04, 0.29)	3.43 (2.88, 4.06)	0.17 (0.11, 0.24)	3.90 (3.59, 4.22)
MD			0.05 (0.00, 0.29)	4.43 (3.54, 5.48)	0.52 (0.25, 0.95)	7.68 (6.49, 9.02)	0.31 (0.11, 0.68)	6.67 (5.57, 7.93)	0.29 (0.17, 0.47)	6.27 (5.64, 6.94)
MN	0.29 (0.10, 0.68)	1.53 (1.00, 2.23)	0.35 (0.13, 0.76)	1.85 (1.27, 2.62)	0.23 (0.06, 0.59)	2.18 (1.54, 2.99)	0.40 (0.16, 0.82)	2.55 (1.86, 2.42)	0.32 (0.20, 0.48)	2.03 (1.71, 2.40)
NM			0.00 (0.00, 0.44)	1.33 (0.61, 2.53)	2.66 (1.58, 4.21)	4.29 (2.87, 6.17)	1.48 (0.71, 2.72)	3.10 (1.92, 4.74)	1.38 (0.92, 2.00)	2.91 (2.22, 3.76)
NY			0.93 (0.38, 1.92)	2.53 (1.53, 3.96)	1.33 (0.64, 2.45)	4.80 (3.36, 6.65)	0.80 (0.29, 1.74)	1.73 (0.92, 2.97)	1.02 (0.65, 1.53)	3.02 (2.35, 3.83)
OR	0.12 (0.01, 0.43)	0.24 (0.06, 0.61)	0.23 (0.06, 0.60)	0.47 (0.20, 0.92)	0.00 (0.00, 0.17)	0.52 (0.24, 0.98)	0.28 (0.09, 0.66)	0.17 (0.04, 0.50)	0.16 (0.08, 0.29)	0.35 (0.22, 0.52)
TN					0.31 (0.10, 0.72)	0.68 (0.34, 1.22)	0.24 (0.07, 0.62)	0.73 (0.37, 1.27)	0.27 (0.13, 0.52)	0.70 (0.45, 1.05)
	0.21 (0.12, 0.34)	2.62 (2.26, 3.02)	0.20 (0.13, 0.29)	2.54 (2.28, 2.83)	0.37 (0.28, 0.48)	2.93 (2.66, 3.22)	0.34 (0.26, 0.45)	2.53 (2.28, 2.79)	0.29 (0.25, 0.35)	2.66 (2.52, 2.81)
Overall

CA, community-associated; HCA, health care-associated.